Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04603417 · ClinicalTrials.gov registry record · NA
Pain Avoidance Behavior and Its Relation to Risk for Opioid Use in Chronic Pain Patients
A NA study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
NCT04603417: Completed NA study, sponsored by The Cleveland Clinic.
NCT04603417 is a NA study that has completed, run by The Cleveland Clinic. The registered enrollment target is 63 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04603417, a NA study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
Study Summary
This study is designed to find behavioral and neurophysiological correlates of pain avoidance behavior among chronic pain patients, controlling for risk for opioid use disorder. Further, traits and risk factors that contribute to pain avoidance behavior will be investigated. The knowledge gained will broaden the current understanding of mechanisms involved in pain avoidance behavior in chronic pain patients, and help devise novel interventions.
Primary Outcome
Brain oscillations during pain avoidance behavior
Interventions
- DIAGNOSTIC_TEST Electroencephalography (EEG)/Magnetoencephalography (MEG)/MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2020-08-15 |
| Est. Completion | 2024-04-30 |
| Phase | NA |
What the finished NCT04603417 record still lists
NCT04603417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Electroencephalography (EEG)/Magnetoencephalography (MEG)/MRI is the first listed.
NCT04603417 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04603417 about?
NCT04603417 is a clinical study titled "Pain Avoidance Behavior and Its Relation to Risk for Opioid Use in Chronic Pain Patients". This study is designed to find behavioral and neurophysiological correlates of pain avoidance behavior among chronic pain patients, controlling for risk for opioid use disorder. Further, traits and risk factors that contribute to pain avoidance behavior will be investigated. The knowledge gained wil...
What is the current status of trial NCT04603417?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2020-08-15. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT04603417?
The interventions under investigation include: Electroencephalography (EEG)/Magnetoencephalography (MEG)/MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04603417?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04603417's enrollment target sits among peer trials
63 1157th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI